Editorial Comment from Dr Yuasa to Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.
作者信息
Yuasa Takeshi
机构信息
Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Ariake, Tokyo, Japan.
出版信息
Int J Urol. 2022 Jul;29(7):740. doi: 10.1111/iju.14920. Epub 2022 May 10.
Abstract
摘要
相似文献
1
Editorial Comment from Dr Yuasa to Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.汤浅博士对积极抗癌治疗对尿路上皮癌和肾细胞癌患者对SARS-CoV-2 BNT162b2疫苗血清学反应的影响的编辑评论。
Int J Urol. 2022 Jul;29(7):740. doi: 10.1111/iju.14920. Epub 2022 May 10.
2
Editorial Comment from Dr Kobayashi to Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.小林博士对尿路上皮癌和肾细胞癌患者中积极抗癌治疗对SARS-CoV-2 BNT162b2疫苗血清学反应的影响的编辑评论。
Int J Urol. 2022 Jul;29(7):739. doi: 10.1111/iju.14919. Epub 2022 Apr 27.
3
Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.活性抗癌治疗对尿路上皮癌和肾细胞癌患者对 SARS-CoV-2 BNT162b2 疫苗血清反应的影响。
Int J Urol. 2022 Jul;29(7):733-739. doi: 10.1111/iju.14882. Epub 2022 Mar 31.
4
Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine.CoronaVac 加强针接种后对 SARS-CoV-2 抗体反应的动力学。
Emerg Infect Dis. 2022 Jun;28(6):1237-1240. doi: 10.3201/eid2806.220061. Epub 2022 Apr 14.
5
BNT162b2 mRNA COVID-19 Vaccine: First Approval.BNT162b2 mRNA COVID-19 疫苗：首次批准。
Drugs. 2021 Mar;81(4):495-501. doi: 10.1007/s40265-021-01480-7.
6
Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?BNT162b2疫苗的第二剂延迟接种：是创新还是错误的推测？
Lancet. 2021 Mar 6;397(10277):879-880. doi: 10.1016/S0140-6736(21)00455-4. Epub 2021 Feb 19.
7
Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.评估接受血液透析患者对 BNT162b2 疫苗的 SARS-CoV-2 抗体反应。
JAMA Netw Open. 2021 Sep 1;4(9):e2123622. doi: 10.1001/jamanetworkopen.2021.23622.
8
Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection.科兴和国药疫苗及未感染过 SARS-CoV-2 医护人员与已感染过 SARS-CoV-2 医护人员接种后中和抗体滴度比较。
J Travel Med. 2022 May 31;29(3). doi: 10.1093/jtm/taac010.
9
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.第三次BNT162b2疫苗接种对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎感染的中和作用
N Engl J Med. 2022 Feb 3;386(5):492-494. doi: 10.1056/NEJMc2119358. Epub 2021 Dec 29.
10
Factors affecting the serologic response to SARS-CoV-2 vaccination in patients with solid tumors: A prospective study.影响实体瘤患者对 SARS-CoV-2 疫苗血清学反应的因素：一项前瞻性研究。
J Infect Chemother. 2022 Sep;28(9):1310-1316. doi: 10.1016/j.jiac.2022.05.021. Epub 2022 Jun 6.
本文引用的文献
1
Switching Patients With Prostate Cancer from GnRH Antagonist to Long-acting LHRH Agonist for Androgen Deprivation: Reducing Hospital Visits During the Coronavirus Pandemic.将前列腺癌患者从促性腺激素释放激素（GnRH）拮抗剂转换为长效促黄体生成素释放激素（LHRH）激动剂进行雄激素剥夺治疗：在冠状病毒大流行期间减少医院就诊次数
Cancer Diagn Progn. 2021 Mar 3;1(1):1-5. doi: 10.21873/cdp.10000. eCollection 2021 Mar-Apr.
2
Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma.活性抗癌治疗对尿路上皮癌和肾细胞癌患者对 SARS-CoV-2 BNT162b2 疫苗血清反应的影响。
Int J Urol. 2022 Jul;29(7):733-739. doi: 10.1111/iju.14882. Epub 2022 Mar 31.
3
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.癌症患者的 COVID-19 疫苗：免疫原性、疗效和安全性。
Nat Rev Clin Oncol. 2022 Jun;19(6):385-401. doi: 10.1038/s41571-022-00610-8. Epub 2022 Mar 11.
4
Vaccination against Cancer or Infectious Agents during Checkpoint Inhibitor Therapy.在检查点抑制剂治疗期间针对癌症或感染因子进行疫苗接种。
Vaccines (Basel). 2021 Nov 25;9(12):1396. doi: 10.3390/vaccines9121396.
5
Factors associated with COVID-19-related death using OpenSAFELY.使用 OpenSAFELY 分析与 COVID-19 相关死亡的因素。
Nature. 2020 Aug;584(7821):430-436. doi: 10.1038/s41586-020-2521-4. Epub 2020 Jul 8.
Zotero 插件